IFN beta + HF lentiviral vector

IFN beta + HF lentiviral vector is an experimental tumor-targeted gene therapy designed for the systemic treatment of multiple myeloma. The therapeutic consists of a self-inactivating lentiviral vector pseudotyped with engineered measles virus hemagglutinin (H) and fusion (F) glycoproteins (HF), which are modified to enable highly specific entry into malignant cells while avoiding healthy tissues. The vector delivers a transgene encoding interferon-beta (IFNβ), a potent cytokine with well-characterized antitumor, anti-angiogenic, and immunomodulatory activities. Upon transduction, the tumor cells serve as local factories for IFNβ production, leading to microenvironmental reprogramming characterized by the induction of pro-inflammatory cytokines (e.g., IFNγ, IP-10) and the suppression of myeloma-promoting factors (e.g., IL-6, TNFα). Preclinical data presented at EHA 2026 demonstrated that intravenous administration of the vector leads to significant reduction in circulating tumor cells, regression of established myeloma lesions, and prolonged survival in systemic xenograft models.

Other names

IFN-beta-expressing HF-pseudotyped lentiviral vectortumor-targeted IFNβ-expressing vectorIFNβ-HF-LV